Focused Ultrasound (FUS) is a therapeutic and diagnostic technology that directs acoustic energy from an array of transducer elements to a precise focal point inside the body, concentrating thermal or mechanical energy at that location while leaving surrounding tissue largely unaffected. Medical devices built on this principle enable non-invasive tissue ablation, neuromodulation, targeted drug delivery, and blood-brain barrier opening.
What is Focused Ultrasound?
Focused ultrasound (FUS) uses phased or geometrically shaped transducer arrays to converge ultrasound waves from multiple directions into a small focal volume, often only a few millimeters in diameter. Outside this focal region, energy density remains low enough that intervening tissue experiences minimal biological effect. Within the focal zone, however, acoustic energy can produce controlled heating, mechanical disruption, cavitation, or transient biological effects depending on the acoustic parameters selected.
From a medical device engineering perspective, FUS combines precision transducer design, high-power electronics, beamforming software, imaging guidance, and closed-loop safety systems. Modern platforms are used for tumor ablation, treatment of movement disorders such as essential tremor, uterine fibroid therapy, pain management, targeted drug delivery, and emerging neuromodulation applications. Depending on intended use and risk, these systems are typically regulated as Class II or Class III medical devices.
Why Focused Ultrasound matters in medical device development
Focused ultrasound devices deliver large amounts of energy into a highly localized tissue volume. Small deviations in targeting, acoustic output, or thermal dose can result in under-treatment or unintended injury to adjacent structures. Consequently, verification requirements extend well beyond conventional medical electronics and include acoustic characterization, beam steering accuracy, thermal modeling, tissue interaction studies, and real-time safety monitoring.
Regulatory agencies expect comprehensive evidence demonstrating both safety and treatment effectiveness. FDA reviewers and EU MDR notified bodies typically evaluate acoustic output measurements, treatment planning algorithms, software verification, thermal safety analysis, risk management, and clinical evidence appropriate to the intended indication.
Development schedules frequently slip when acoustic simulations, tissue models, or temperature monitoring strategies are left until late in the program. Programs that integrate ISO 14971 risk management, IEC 62366-1 usability engineering, and system verification early generally experience fewer redesign cycles during regulatory review.
How Focused Ultrasound works
A focused ultrasound system integrates multiple specialized subsystems that operate together to deliver controlled therapeutic energy.
- Transducer array. Piezoelectric or capacitive micromachined ultrasonic transducer (CMUT) elements arranged in phased or curved geometries generate ultrasound waves that converge at a programmable focal point.
- Beamforming electronics. High-power drive electronics precisely control the phase, amplitude, and timing of each transducer element, allowing electronic steering and shaping of the focal zone without moving the transducer.
- Acoustic coupling system. Degassed water baths, gel pads, membranes, or balloon interfaces efficiently transfer ultrasound energy into tissue while minimizing reflection and attenuation.
- Image guidance. MRI or diagnostic ultrasound provides anatomical targeting, treatment planning, real-time monitoring, and confirmation of treatment location. MRI-guided systems commonly use MR thermometry to monitor tissue temperature during therapy.
- Monitoring and safety systems. Temperature monitoring, cavitation detection, patient motion sensing, and automatic shutdown logic continuously verify that treatment remains within predefined safety limits.
Medical device development follows the standard design control framework while adding specialized acoustic verification activities. Basic electrical safety and essential performance are evaluated under IEC 60601-1, while IEC 60601-2-62 specifies particular requirements for high-intensity therapeutic ultrasound equipment. Software responsible for beam steering, treatment planning, or energy delivery follows IEC 62304, often at Software Safety Class B or C because software failures may result in serious patient harm. Quality management is maintained under ISO 13485, with risk management throughout development according to ISO 14971.
Common challenges and best practices
Accurate acoustic modeling is one of the most technically demanding aspects of FUS development. Real human tissue contains interfaces such as bone, air cavities, blood vessels, and varying tissue densities that distort ultrasound propagation. Simulation alone is rarely sufficient, making phantom testing, ex vivo experiments, and animal studies important parts of verification.
Thermal monitoring should be incorporated from the beginning rather than added after hardware development. MRI thermometry or alternative monitoring techniques directly influence system architecture, software design, and clinical workflow.
The acoustic coupling interface is another common source of problems. Small air bubbles trapped within coupling media can scatter or reflect ultrasound energy, reducing treatment efficiency and shifting the focal point. Careful control of degassing procedures and coupling materials is therefore essential.
Verification programs should extend well beyond nominal operating conditions. Testing should evaluate maximum acoustic power, extreme focal depths, off-axis steering, patient motion, varying tissue properties, and worst-case thermal accumulation. These scenarios frequently receive close attention during regulatory review.
Strong development programs maintain a single, validated thermal dose model across engineering, clinical, and regulatory teams while integrating acoustic verification into system-level verification from the earliest design phases.
How SJML helps with Focused Ultrasound
SJML supports focused ultrasound device development from early feasibility through commercialization. Its multidisciplinary engineering teams work across mechanical design, high-power electronics, embedded software, systems engineering, and manufacturing to develop complex therapeutic ultrasound platforms.
Development activities include transducer integration, embedded control software, electrical safety engineering, and system verification supported by in-house IEC 60601 testing capabilities. SJML’s QARA specialists provide ISO 14971 risk management, regulatory strategy, clinical evaluation support, and technical documentation preparation for FDA and EU MDR submissions. Manufacturing capabilities include precision electromechanical assembly, controlled manufacturing environments, and quality systems aligned with ISO 13485 for complex ultrasound-based medical devices.
Talk to SJML’s engineering team →
Frequently asked questions
No. High-Intensity Focused Ultrasound (HIFU) is one application within the broader focused ultrasound field. HIFU uses high acoustic power to thermally ablate tissue, while focused ultrasound also includes lower-intensity applications such as neuromodulation, blood-brain barrier opening, targeted drug delivery, and other non-ablative therapies.
Classification depends on intended use, target anatomy, and therapeutic risk. Many therapeutic focused ultrasound systems are regulated as Class II or Class III devices in both the United States and Europe. Combined imaging-and-therapy platforms are generally classified according to their highest-risk therapeutic function.
Yes, although many modern therapeutic systems incorporate real-time image guidance. Some applications rely on pre-planned targeting and fixed geometry, while MRI-guided or ultrasound-guided systems provide continuous visualization, treatment verification, and temperature monitoring that significantly improve treatment precision and safety.
IEC 60601-2-62 specifies the particular requirements for the basic safety and essential performance of high-intensity therapeutic ultrasound equipment. It supplements the general requirements of IEC 60601-1 with additional provisions covering acoustic output, treatment safety, labeling, and performance verification. Software controlling therapy is typically developed under IEC 62304 alongside these requirements.
Both technologies use acoustic energy, but their therapeutic objectives differ. Lithotripsy delivers high-energy shock waves or focused acoustic pulses specifically to fragment kidney stones and other calcified structures. Focused ultrasound encompasses a broader range of applications, including tissue ablation, neuromodulation, targeted drug delivery, and blood-brain barrier opening. Although some underlying transducer technologies overlap, the biological mechanisms and clinical goals are different.
Related terms
- High-Intensity Focused Ultrasound (HIFU)
- Therapeutic Ultrasound
- MRI-Guided Focused Ultrasound
- Design Verification
- Risk Management (ISO 14971)
